FUNDAMENTALS · Fundamentals · NZ Healthcare

Ryman Healthcare (RYM) Fundamentals 2026 — Revenue Analysis | SniperIQ

Ryman Healthcare (RYM) is a NZ-listed Healthcare company in Medical - Care Facilities with a market capitalization of A

.9B, trading at A
.82 on the ASX. This SniperIQ fundamentals page covers Ryman Healthcare's valuation, profitability (net margin -21.5%), revenue (NZD 804M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
.9B
Net Margin-21.5%
Revenue (FY25)NZD 804M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Ryman Healthcare's market cap?

Ryman Healthcare (RYM) has a market capitalization of approximately A

.9B, trading at A
.82 on the ASX. Market cap moves with the live share price.

What is Ryman Healthcare's P/E ratio?

Ryman Healthcare's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Ryman Healthcare?

Ryman Healthcare runs a net profit margin of -21.5%, a gross margin of -2.2%, and an operating margin of -2.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Ryman Healthcare generate?

Ryman Healthcare reported revenue of NZD 804M for fiscal year 2025, with net income of -NZD 173M and earnings per share (EPS) of -0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Ryman Healthcare pay a dividend?

Ryman Healthcare does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Ryman Healthcare financially healthy?

Ryman Healthcare carries a debt-to-equity ratio of 0.39x and a current ratio of 0.55x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Ryman Healthcare a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ryman Healthcare (RYM) the key facts are: market cap A

.9B, revenue NZD 804M, 52-week range 1.615-2.64. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Ryman Healthcare's full fundamentals live

Get Ryman Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: UFP Technologies (UFPT) fundamentals · Iovance Biotherapeutics (IOVA) fundamentals · Tyra Biosciences (TYRA) fundamentals · Damora Therapeutics (DMRA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons